| | | | | | What you need to know about the coronavirus today | | | China joins COVAX China said it has joined the COVAX global COVID-19 vaccine initiative co-led by the World Health Organization (WHO), becoming the biggest economy to date to pledge support to help buy and distribute the shots fairly.
The move by China, where the virus was first reported, comes as it holds separate talks with the WHO to have its locally produced COVID-19 vaccines assessed for international use.
China has at least four experimental vaccines in the final stage of clinical trials - two are developed by state-backed China National Biotec Group (CNBG), and the remaining two are from Sinovac Biotech and CanSino Biologics, respectively.
China joins some 168 countries that have already announced their participation in COVAX including 76 wealthy, self-financing ones. But neither the United States nor Russia have joined the program. The COVAX initiative aims to deliver at least 2 billion doses of vaccines by the end of 2021.
Takeda starts blood plasma trials Japan’s Takeda Pharmaceutical said an alliance of drugmakers it spearheads has enrolled its first patient in a global clinical trial of a blood plasma treatment for COVID-19 after months of regulatory delays.
Patients will be treated with Gilead Science Inc’s Remdesivir alongside the plasma treatment, a hyperimmune globulin therapy derived from blood plasma, which offers a standardized dose of antibodies and doesn’t need to be limited to patients with matching blood types.
The WHO has urged caution about plasma treatments for COVID-19 saying evidence they work is “low quality”, even as the United States issued emergency authorization for such therapies.
Eli Lilly antibody treatment supply planned for low and middle-income countries Drugmaker Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries.
As part of the deal, Lilly said it will make antibody therapies available to lower-income countries prior to April 2021, but did not elaborate on the number of doses.
Lilly in September partnered with Amgen to increase supply of its antibody therapies, a day after data showed Lilly’s single antibody therapy, LY-CoV555, helped cut hospitalization and emergency room visits for COVID-19 patients.
Track the global spread with Reuters live interactive graphic updated regularly throughout each day. | | | | | | Reuters reporters and editors around the world are investigating the response to the coronavirus pandemic.
We need your help to tell these stories. Our news organization wants to capture the full scope of what’s happening and how we got here by drawing on a wide variety of sources.
Are you a government employee or contractor involved in coronavirus testing or the wider public health response? Are you a doctor, nurse or health worker caring for patients? Have you worked on similar outbreaks in the past? Has the disease known as COVID-19 personally affected you or your family? Are you aware of new problems that are about to emerge, such as critical supply shortages?
We need your tips, firsthand accounts, relevant documents or expert knowledge. Please contact us at coronavirus@reuters.com.
We prefer tips from named sources, but if you’d rather remain anonymous, you can submit a confidential news tip. Here’s how. | | | | | | | | | | Top Stories on Reuters TV | | | | | | | |
No comments:
Post a Comment